Human umbilical cord mesenchymal stem cells alleviate acute myocarditis by modulating endoplasmic reticulum stress and extracellular signal regulated 1/2-mediated apoptosis

CHANGYI ZHANG¹, GUICHI ZHOU², CHANXIN CAI², JINDI LI², FEN CHEN³,⁴, LICHUN XIE³,⁴, WEI WANG¹,⁵, YONGGANG ZHANG¹,⁵, XIULAN LAI²,⁵ and LIAN MA²,⁵

Abstract. Acute myocarditis is a non-ischemic inflammatory disease of the myocardium, and there is currently no standard treatment. Mesenchymal stem cells (MSCs) can alleviate myosin-induced myocarditis; however, the mechanism has not been clearly elucidated. In the present study, the authors investigated the ability of human umbilical cord MSCs (HuMSCs) to attenuate myocardial injury and dysfunction during the acute phase of experimental myocarditis. Male Lewis rats (aged 8 weeks) were injected with porcine myosin to induce myocarditis. Cultured HuMSCs (1x10⁶ cells/rat) were intravenously injected 10 days following myosin injection. A total of 3 weeks following injection, this resulted in severe inflammation and significant deterioration of cardiac function. HuMSC transplantation attenuated infiltration of inflammatory cells and adverse cardiac remodeling, as well as reduced cardiomyocyte apoptosis. Furthermore, it was identified that HuMSC transplantation suppressed endoplasmic reticulum stress and extracellular signal-regulated kinase (ERK)1/2 signaling in experimental autoimmune myocarditis (EAM). The reduced number of TUNEL-positive apoptotic cells in myocardial sections from HuMSC-treated EAM rats compared with control demonstrates HuMSCs’ anti-apoptotic function. Based on these data, the author suggested that treatment with HuMSCs inhibits myocardial apoptosis in EAM rats, ultimately protecting them from myocardial damage. The conclusion demonstrated that HuMSC transplantation attenuates myocardial injury and dysfunction in a rat model of acute myocarditis, potentially via regulation of ER stress, ERK1/2 signaling and induction of cardiomyocyte apoptosis.

Introduction

Myocarditis is defined as an inflammatory infiltration of the myocardium with necrosis and/or degeneration of cardiomyocytes (1). Viruses are the primary cause of myocarditis; however, there are additional infectious causes of myocarditis, including Borrelia burgdorferi and Trypanosoma cruzi (2). There are a wide range of myocarditis symptoms, from mild dyspnea, arrhythmias and chest pain that resolves itself without specific therapy, to cardiogenic death (2). The major long-term consequence is dilated cardiomyopathy with chronic heart failure, for which appropriate treatment remains a significant clinical challenge.

A rat model of experimental autoimmune myocarditis (EAM) resembles human giant cell myocarditis and has been widely used in previous studies (3,4). Previous reports suggested that oxidative stress results in myocardial apoptosis, which serves an important role in the progression of EAM (5,6). Oxidative stress may activate mitogen-activated protein kinase (MAPK) signaling pathways and endoplasmic reticulum (ER) stress, both of which lead to myocardial apoptosis and myocardial damage (7). A previous study demonstrated that intravenous injection of bone marrow mesenchymal stem cells (BMSCs) may alleviate myosin-induced myocarditis (8). However, the invasiveness of obtaining bone marrow and the low numbers of MSCs yielded following processing limits its clinical potential. In previous years, human umbilical cord-derived mesenchymal stem cells (HuMSCs), which are generally discarded as medical waste following delivery, have become an alternate source of MSCs (9). Cluster of
differentiation (CD)29, CD44, CD59, CD90 and CD105 are expressed in HuMSCs. Markers of hematopoietic cells, including CD14, CD33, CD34, CD28, CD45 and CD117, and important graft-vs.-host disease (GVHD) markers, including CD80, CD86 and CD40, are not detectable or only weakly expressed in HuMSCs (10). Therefore, it has been hypothesized that HuMSCs may be broadly used in regenerative medicine without graft rejection reactions (11). However, the capacity of HuMSCs during EAM remains undetermined.

The current study investigated whether intravenous HuMSCs may improve cardiac function and alleviate myocardial inflammation in rats with myosin-induced myocarditis, as well as evaluating the potential underlying mechanisms.

Materials and methods

Animals. Male Lewis rats (n=24; aged 8 weeks; weight 180-200 g) were purchased from Vital River Laboratories Co., Ltd. (Beijing, China) and were maintained in our animal facilities with air-conditioning at Shantou University Medical College, under constant temperature and humidity conditions with a 12:12-h light-dark cycle. All rats had free access to food and water. Throughout the studies, all animals were treated in accordance with the institutional guidelines for animal experiments. Ethical approval was obtained from the Institutional Review Board of Shantou University Medical College (Shantou, China).

Preparation of HuMSCs. Ethical approval was obtained from the Institutional Review Board of Shantou University Medical College (Shantou, China). HuMSCs were prepared as previously described (10). A total of 5 patients were involved in the study, and written informed consent was obtained from all patients. Human umbilical cords from consenting patients who underwent full-term Caesarian sections were collected immediately into a sterilized 50 ml tubes, washed with phosphate-buffered saline (PBS), and cut into 2- to 3-cm thick sections. Following dissection of the arteries and veins, the remaining tissue, the Wharton’s jelly, was sectioned into smaller fragments and transferred to 75 cm² flasks containing Dulbecco’s Modified Eagle’s medium/F12 media (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) supplemented with 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA), 100 µg/ml penicillin/streptomycin (Beyotime Institute of Biotechnology, Haimen, China), 1 g/ml amphotericin B (Gilead Sciences, Inc., Foster City, CA, USA), 5 ng/ml epidermal growth factor (EGF; Invitrogen; Thermo Fisher Scientific, Inc.), and 5 ng/ml basic fibroblast growth factor (bFGF; Sigma-Aldrich; Merck KGaA). Cultures remained undisturbed for 5-7 days at 37°C in 5% CO₂ to allow migration of cells from the explants. Subsequently, the media was replaced.

EAM induction. Purified porcine cardiac myosin (Sigma-Aldrich; Merck KGaA) was dissolved in 0.01 M PBS and emulsified with an equal volume of complete Freund's adjuvant supplemented with10 mg/ml Mycobacterium tuberculosi (Sigma-Aldrich; Merck KGaA). On day 0, rats received a single immunization at two subcutaneous sites (both footpads) with a total of 0.2 ml emulsion per rat. Rats not subjected to immunization were included as a control group (n=8).

A total of 16 immunized rats were randomly divided into two groups. Rats were randomly assigned into the following two groups: Control group, 0.2 ml PBS only (n=8); HuMSCs group, 0.2 ml HuMSCs (1x10⁶ cells/animal; n=8). A total of 10 days following myosin injection, HuMSCs or vehicle (PBS) were administered intravenously via the tail vein.

Echocardiographic studies. Echocardiography was performed 21 days following the myosin injection. Rats were anesthetized with 1.5-2.0% volume of isoflurane in air (Sigma-Aldrich; Merck KGaA). A 13-MHz probe was placed at the left fourth intercostal space for imaging using two-dimensional echocardiography (AcusonAntares, Siemens AG, Munich, Germany). Left ventricular systolic dimension (LVDs), left ventricular diastolic dimension (LVDD), interventricular septal thickness (IVS), left ventricular posterior wall thickness (LVPW) and fractional shortening (FS%) were measured and recorded as the mean for three beats. Fractional shortening (%) was calculated as [(LVDD-LVDs)/LVDD]x100%. Investigators blinded to the treatment group performed the echocardiography studies and all analyses were performed offline.

Histopathological studies. Following echocardiographic analyses, rats were sacrificed by cervical dislocation. Hearts were excised above the origin of the great vessels 21 days after the myosin injection. Hearts were fixed in 4% paraformaldehyde for 6 h at 4°C, embedded in paraffin, sectioned to 4-µm thickness, and stained with hematoxylin and eosin (H&E). A cardiovascular pathologist with no knowledge of the experimental groups evaluated H&E-stained sections. Myocardial injury and inflammation were characterized by assigning histoscopes to every fifth cross section, according to a previously published 6-tier scoring system (grade 0, no inflammation; grade 1, cardiac infiltration in <5% of the cardiac sections; grade 2, 6-10% infiltration; grade 3,11-30% infiltration; grade 4, 31-50% infiltration; and grade 5, infiltration in >50% of cardiac sections) (12,13).

Western blotting. Heart tissues were homogenized in ice-cold radioimmunoprecipitation assay lysis buffer (Beyotime Institute of Biotechnology, Haimen, China). Following centrifugation (12,000 x g for 10 min at 4°C), supernatants were collected and the total protein concentration in samples was measured by use of a BCA Protein Assay kit (Beyotime Institute of Biotechnology), according to the manufacturer's protocol. For western blotting assays, 30 µg of total protein was separated by 7.5% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto polyvinylidene difluoride (PVDF) membranes (EMD Millipore, Billerica, MA, USA). Filters were blocked with 5% non-fat dry milk in TBST (20 mM Tris, pH 6.8, 137 mM NaCl, 0.1% Tween-20) overnight at 4°C, washed, and incubated overnight at 4°C with a 1:1,000 dilution of primary antibodies in blocking solution. Washing was conducted four times with TBST, for 10 min each, with constant shaking. The following primary antibodies were used: GAPDH (catalog no. D4C6R), extracellular signal-regulated kinase (ERK)-1/2 (catalog no. 9258), phosphorylated (p)-ERK-1/2 (catalog no. 4668), p38 MAPK...
ameliorated protein expression levels of ERK 1/2. 

Discussion

In the present study, the therapeutic potential of HuMSCs in the acute phase of myocarditis was investigated. In a rat model of acute myocarditis, intravenous administration of HuMSCs 10 days following myosin injection significantly improved cardiac function. Echocardiographic analyses demonstrated LV remodeling with increased LVDs, LVDd and reduced FS in vehicle-treated EAM rats compared with normal rats, indicating impaired systolic and diastolic function of the myocardium. HuMSC treatment positively affected LV remodeling by significantly reversing the increased LVDs and LVDd, and reducing FS. Pathological findings in the heart 21 days following myosin injection indicated that EAM rats in the control group suffered extensive inflammatory cellular infiltration, whereas rats treated with HuMSCs exhibited significantly less infiltration. Based on these results, HuMSCs demonstrated protective effects in myocardial inflammation.

Myosin-induced EAM contributes to a model that is similar to giant cell myocarditis in humans with three phases: Antigen-priming (from days 0 to 14), autoimmune response (from days 14 to 21), and a chronic phase featuring cardiac remodeling and fibrosis (3). Although EAM pathogenesis has remains to be fully elucidated, MAPK signaling pathways...
and ER stress-induced myocardial apoptosis are likely to be involved.

MAPKs are a group of serine/threonine protein kinases. There are three MAPK subfamilies: ERK, c-Jun N-terminal kinase and p38-MAPK. Overexpression of mitogen activated protein kinase kinase (MEK) 1, the upstream activator of ERK 1/2, results in cardiomyocyte hypertrophy in vitro (14). The MEK/ERK cascade serves a role in fibrotic diseases (15,16) and affects lymphocyte activation and differentiation (17-19). In addition, the MEK/ERK signaling pathway enhances the production of diverse proinflammatory cytokines, including interleukin (IL)-β, tumor necrosis factor-α and IL-6 (20-22). The MEK/ERK signaling pathway is targeted for the treatment of rheumatoid arthritis (23), and is involved in IL-17-mediated cardiac fibrosis in EAM (24). Activation of ERK1/2 serves a role in cardiomyocyte apoptosis caused by doxorubicin (25). Proteomic and biochemical analyses further revealed that ERK-1/2 signaling and ER stress mediates cardiomyocyte apoptosis in EAM (26).

In the present study, p-ERK1/2 expression was significantly increased in EAM rats treated with the vehicle. However, HuMSC supplementation protected against cardiac damage as evidenced by decreased levels of p-ERK1/2 proteins. However, p38-MAPK levels did not differ among the three groups. These results confirmed the involvement of ERK1/2 signaling in EAM, as well as indicating that HuMSC treatment may

Figure 1. Experiments comparing cellular infiltration, levels of apoptosis and systolic and diastolic components in normal cells, control cells and HuMSCs. (A) H&E staining of left ventricular tissue slices (magnification, x100). TUNEL staining of left ventricular tissue slices depicting apoptotic nuclei (magnification, x400). Echocardiography in four chambers. (B) Histoscores of H&E staining reflecting levels of cardiac infiltration. (C) Bar graphs presenting the average number of TUNEL-positive cells per field. (D) Quantification of LVDs, LVDd and FS. Data are expressed as the mean ± standard deviation. **P<0.01 vs. Normal, ##P<0.01 vs. Control. HuMSCs, human umbilical-derived mesenchymal stem cells; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling; LVDs, left ventricular systolic dimension; LVDd, left ventricular diastolic dimension; FS, fractional shortening.
authors suggested that treatment with HuMSCs is effective for the prevention of myocardial apoptosis in EAM rats and may protect them from myocardial damage.

In conclusion, the present study demonstrated that the protective effects of intravenously administered HuMSCs in EAM result from regulation of ER stress and ERK1/2 signaling-mediated apoptosis. As HuMSCs are available in large numbers using non-invasive procedures, these findings provide a novel perspective for the treatment of acute myocarditis.

Acknowledgements

The current study was supported by grants from the National Natural Science Foundation of China (grant no. 81070478), the Science and Technology Program of Guangdong Province (grant no. 2012B0031800443), the Science and Technology Program Project of Shantou (grant no. 2012165 and 2013), the Basic and Clinical Scientific Research Foundation of Shantou University Medical College (grant no. 201410), the Science and Technology Program of Shenzhen (grant no. JCYJ20150402092905162) and the Research Project of Health and Family Planning Commission of Shenzhen Municipality (grant no. 201501053).

References

1. Aretz HT, Billingham ME, Edwards WD, Factor SM, Fallon JT, Fenoglio JJ Jr, Olsen EG and Schoen FJ: Myocarditis. A histopathologic definition and classification. Am J Cardiovasc Pathol 1: 3-14, 1987.
2. Cooper LT Jr: Myocarditis. N Engl J Med 360: 1526-1538, 2009.
3. Kodama M, Hanawa H, Saeki M, Hosono H, Inomata T, Suzuki K and Shibata A: Rat dilated cardiomyopathy after autoimmune giant cell myocarditis. Circ Res 75: 278-284, 1994.
4. Kodama M, Matsumoto Y, Fujimura W, Masani F, Izumi T and Shibata A: A novel experimental model of giant cell myocarditis induced in rats by immunization with cardiac myosin fraction. Clin Immunol Immunopathol 57: 250-262, 1990.
5. Alter P, Jobmann M, Meyer E, Pankweiss S and Maisch B: Apoptosis in myocarditis and dilated cardiomyopathy: Does enterovirus genome persistence protect from apoptosis? An endomycocardial biopsy study. Cardiovasc Pathol 10: 229-234, 2001.
6. Lowenstein CJ: Exogenous thioredoxin reduces inflammation in autoimmune myocarditis. Circulation 110: 1178-1179, 2004.
7. Arumugam S, Thandavasaryan RA, Veeraveedu PT, Ma M, Girdhuran VV, Arrozal W, Sari FR, Sukumaran V, Lakshmanan A, Soetikno V, et al: Modulation of endoplasmic reticulum stress and cardiomyocyte apoptosis by mulberry leaf diet in experimental autoimmune myocarditis rats. J Clin Biochem Nutr 50: 139-144, 2012.
8. Ohnishi S, Yanagawa B, Tanaka K, Miyahara Y, Obata H, Kataoka M, Kodama M, Ishibashi-Ueda H, Kangawa K, Kitamura S and Nagaya N: Transplantation of mesenchymal stem cells attenuates myocardial injury and dysfunction in a rat model of acute myocarditis. J Mol Cell Cardiol 42: 88-97, 2007.
9. McElreavey KD, Irvine AI, Ennis KT and McLean WH: Isolation, culture and characterisation of fibroblast-like cells derived from the Wharton's jelly portion of human umbilical cord. Biochem Soc Trans 19: 298-299, 1991.
10. Ma L, Feng XY, Cui BL, Law F, Jiang XW, Yang LY, Xie QD and Huang TH: Human umbilical cord Wharton's jelly-derived mesenchymal stem cells differentiation into nerve-like cells. Chin Med J (Engl) 118: 1987-1993, 2005.
11. Weiss ML, Mitchell KE, Hix JE, Medcetty S, El-Zarkouny SZ, Grieger D and Troyer DL: Transplantation of porcine umbilical cord matrix cells into the rat brain. Exp Neurol 182: 288-299, 2003.
12. Goser S, Otl W, Brodner A, Dengler TJ, Torzewski J, Egashira K, Rose NR, Katus HA and Kaya Z: Critical role for monocyte chemotactic protein 1 and macrophage inflammatory protein-1alpha in induction of experimental autoimmune myocarditis and effective anti-monocyte chemotactic protein-1 gene therapy. Circulation 112: 3400-3407, 2005.
13. Zimmermann O, Homann JM, Bangert A, Müller AM, Hristov G, Goese S, Wiehe JM, Zittrich S, Rottbauer W, Torzewski J, et al: Successful use of mRNA-nucleic acid for overexpression of interleukin-10 in murine monocytes/macrophages for anti-inflammatory therapy in a murine model of autoimmune myocarditis. J Am Heart Assoc 1: e003293, 2012.

14. Ueyama T, Kawashima S, Sakoda T, Rikitake Y, Ishida T, Kawai M, Yamashita T, Ishido S, Hotta H and Yokoyama M: Requirement of activation of the extracellular signal-regulated kinase cascade in myocardial cell hypertrophy. J Mol Cell Cardiol 32: 947-960, 2000.

15. Stratton R, Rajkumar V, Ponticos M, Nichols B, Shiwen X, Black CM, Abraham DJ and Leask A: Prostacyclin derivatives prevent the fibrinotic response to TGF-beta by inhibiting the Ras/MEK/ERK pathway. FASEB J 16: 1949-1951, 2002.

16. Stratton R, Shiwen X, Martini G, Holmes A, Leask A, Haberberger T, Martin GR, Black CM and Abraham D: Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest 108: 241-250, 2001.

17. Chen D, Heath V, O’Garra A, Johnston J and McMahon M: Sustained activation of the ras-ERK pathway elicits cytokine unresponsiveness in T cells. J Immunol 163: 5796-5805, 1999.

18. DeSilva DR, Jones EA, Favata MF, Jaffee BD, Magolda RL, Trzaskos JM and Scherle PA: Inhibition of mitogen-activated protein kinase kinase blocks T cell proliferation but does not induce or prevent anergy. J Immunol 160: 4175-4181, 1998.

19. Pagès G, Guérin S, Grall D, Bonino F, Smith A, Anjuere F, Auberge P and Pouysségur J: Defective thymocyte maturation in p44 MAP kinase (Erk 1) knockout mice. Science 286: 1374-1377, 1999.

20. Dumitru CD, Ceci JD, Tsatsanis C, Kontoyiannis D, Stamatakis K, Lin JH, Patriotis C, Jenkins NA, Copeland NG, Kollias G and Tsichlis PN: TNF-alpha induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway. Cell 103: 1071-1083, 2000.

21. Scherle PA, Jones EA, Favata MF, Daulerio AJ, Covington MB, Nurnberg SA, Magolda RL and Trzaskos JM: Inhibition of MAP kinase prevents cytokine and prostaglandin E2 production in lipopolysaccharide-stimulated monocytes. J Immunol 161: 5681-5686, 1998.

22. Tuyt LM, Dokter WH, Birkenkamp K, Koopmans SB, Lumen C, Kruijer W and Vellenga E: Extracellular-regulated kinase 1/2, Jun N-terminal kinase, and c-Jun are involved in NF-kappa B-dependent IL-6 expression in human monocytes. J Immunol 162: 4893-4902, 1999.